Drug Insights

Expert Tips for Searching Hydralazine on Synapse

19 February 2024
2 min read

Hydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension. Developed by Novartis, Hydralazine Hydrochloride works as AOC3 inhibitors, aiding in the management of essential hypertension, severe hypertension, heart failure, pre-eclampsia, and eclampsia. Its mechanism of action has made it a reliable option for individuals requiring immediate action for hypertension. As a trusted medication in the field of hypertension treatment, Hydralazine Hydrochloride has helped countless individuals manage their blood pressure and maintain healthy lifestyles. Click on the image below to begin the exploration journey of Hydralazine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

China Grants First-Ever Approval to Crovalimab for Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapy
Latest Hotspot
3 min read
China Grants First-Ever Approval to Crovalimab for Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapy
19 February 2024
Chugai Pharmaceutical announced that China's National Medical Products Administration approved its innovative C5 monoclonal antibody, crovalimab.
Read →
Exploring Riluzole's R&D successes and its clinical results at the 2024 ASCO_GI
Exploring Riluzole's R&D successes and its clinical results at the 2024 ASCO_GI
19 February 2024
Colorectal cancer (CRC) ranks second in US cancer deaths. 5-fluorouracil (5-FU) therapies with targeted drugs are the go-to for advanced cases.
Read →
In a Phase 2b trial, the oral peptide JNJ-2113 showed promise for moderate to severe psoriasis
Latest Hotspot
3 min read
In a Phase 2b trial, the oral peptide JNJ-2113 showed promise for moderate to severe psoriasis
19 February 2024
In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.
Read →
Navigating Health Information: How to Use Synapse to Search for Oxytocin
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Oxytocin
19 February 2024
Oxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.